Tumor metabolic volume by (18)F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50 - Yamaguchi, O; Kaira, K; Hashimoto, K (Scientific reports, 2020)
et al.